![CDDF’s Selection As Ad Hoc Representative of the Multi-Stakeholder Platform Advisory Group (MSP AG) Under the Accelerating Clinical Trials in the EU (ACT EU)](https://cddf.org/wp-content/uploads/2024/01/Copy-of-Dark-Purple-and-Blue-Texture-Blur-Circle-Business-Marketing-Presentation-1080x675.jpg)
CDDF’s Selection As Ad Hoc Representative of the Multi-Stakeholder Platform Advisory Group (MSP AG) Under the Accelerating Clinical Trials in the EU (ACT EU)
The Cancer Drug Development Forum is proud to announce its selection as an ad hoc representative of the Multi-Stakeholder Platform Advisory Group (MSP AG) under the Accelerating Clinical Trials in the EU (ACT EU). The ACT EU initiative is run by the European...
![Gain valuable perspectives from CDDF participants and get an inside look at the CDDF Multi-stakeholder workshop on Biomarkers in Precision Oncology (Nov 2023)](https://cddf.org/wp-content/uploads/2024/01/Capture-1080x675.jpg)
Gain valuable perspectives from CDDF participants and get an inside look at the CDDF Multi-stakeholder workshop on Biomarkers in Precision Oncology (Nov 2023)
Take a look at the interviews with participants from the CDDF Multi-stakeholder Workshop on “Biomarkers in Delivering Drug Development-Related Precision Oncology (13-14 November 2023, Amsterdam) and gain valuable perspectives from diverse stakeholders. Collaboration...
![NEW PUBLICATION-WHITE PAPER: Histology Independent Drug Development – Is This the Future for Cancer Drugs?](https://cddf.org/wp-content/uploads/2024/01/Dark-Purple-and-Blue-Texture-Blur-Circle-Business-Marketing-Presentation-1080x675.jpg)
NEW PUBLICATION-WHITE PAPER: Histology Independent Drug Development – Is This the Future for Cancer Drugs?
The Cancer Drug Development Forum (CDDF) is delighted to announce that the White Paper has been developed following its ‘Histology Independent Drug Development – Is This the Future for Cancer Drugs?’ workshop, which took place on 14-15th November 2022, in Amsterdam....
![CDDF’s New Board Members: A Warm Welcome to Dr. Christian Schneider, Dr. Fergus Sweeney and Dr. Rosa Giuliani](https://cddf.org/wp-content/uploads/2023/12/Welcome-to-the-New-Members-2-1080x675.gif)
CDDF’s New Board Members: A Warm Welcome to Dr. Christian Schneider, Dr. Fergus Sweeney and Dr. Rosa Giuliani
With great pleasure, the Cancer Drug Development Forum (CDDF) announces the appointment of Dr. Christian Schneider, Dr. Fergus Sweeney, and Dr. Rosa Giuliani to its Board of Directors for a three-year term, effective 5 December, 2023. We warmly welcome these new...
![Executive Summary of the CDDF Workshop on Biomarkers in Precision Oncology (13-14 Nov 2023, NL)](https://cddf.org/wp-content/uploads/2023/11/Capture-1-1080x675.jpg)
Executive Summary of the CDDF Workshop on Biomarkers in Precision Oncology (13-14 Nov 2023, NL)
The Cancer Drug Development Forum (CDDF) is delighted to announce that its executive summary of the CDDF workshop on Biomarkers in Precision Oncology (13-14 Nov 2023, NL) has been published and is available to all our stakeholders. This insightful workshop brought...
![TAKE-HOME MESSAGES: CDDF Multi-Stakeholder Workshop – The Critical Role of Biomarkers in Delivering Drug Development-Related Precision Oncology](https://cddf.org/wp-content/uploads/2023/11/Untitled-design-2-pdf.jpg)
TAKE-HOME MESSAGES: CDDF Multi-Stakeholder Workshop – The Critical Role of Biomarkers in Delivering Drug Development-Related Precision Oncology
Read the take-home messages from the CDDF multi-stakeholder workshop on The critical role of Biomarkers in delivering drug development-related precision oncology: SESSION 1: SETTING THE SCENE OF BIOMARKERS Key takeaways: Biomarkers are critical in the diagnosis...